Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotechnology
EPIC: STI
Latest Price: A$0.00  (0,00%)
52-week High: A$0.00
52-week Low: A$0.00
Market Cap: A$4.45M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Stirling Products
www.stirlingproducts.net

Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties.  Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.

The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.

Stirling operates through three main business units each managed by proven industry specialist managers:

- Pharmaceutical & Healthcare
- Research & Development
- Animal Products

Pdf

Stirling Products appoints former Pfizer director as CEO

6th May 2011, 4:24 am

Stirling Products (ASX: STI) has appointed a new chief executive officer and consultant to the company.

Jeremy Cocks, Stirling’s new incoming chief executive offer, has previously held positions as a Director of Pfizer (NYSE: PFE) a US$163 billion valued company where he headed new products marketing and business development. He was recently Head of Marketing and Technical Services at Novartis (NYSE: NVS), valued at US$157 billion.

Cocks has expertise in the pharmaceutical animal health sector and has proven sales, marketing and management experience in Australia, the US and the UK.

The appointment will be formalised by 6 June 2011 and remains subject to a probationary term of three months and Board approval.

The company has also appointed John Botten to act as an advisor and consultant to Stirling.

Botten will advise and assist the company in the global commercialisation of its TeleMedCare e – Health vital signs monitoring business.

He has multi-national experience including 31 years at IBM (NYSE: IBM) and acted as Director at the computer hardware giant for 12 year including four years at IBM's European Headquarters in France as the Product Director resposible for the marketing of IBM's large systems across EMEA.

Botten also spent six years on the Board of the UK Forensic Science Service and is currently chairman of The Learning Machine, an open source education technology company.

Stirling has entered advanced stages of discussion with a UK broker and institutions regarding the potential dual listing of the company on the London Stock Exchange Alternative Investment Market, and subject to this, Botten has offered his services as a UK independent director.

Peter Boonen, managing director, said “Stirling is indeed fortunate to have the opportunity of securing the services of a new CEO who has proven management skills within the industry and can lead the company in the next phase of business development.”

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.